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Abstract
Although there is a strong association between osteoporosis and skeletal muscle atrophy/dysfunction, the functional
relevance of a particular biological pathway that regulates synchronously bone and skeletal muscle physiopathology is
still elusive. Receptor-activator of nuclear factor κB (RANK), its ligand RANKL and the soluble decoy receptor
osteoprotegerin (OPG) are the key regulators of osteoclast differentiation and bone remodelling. We thus hypothesized
that RANK/RANKL/OPG, which is a key pathway for bone regulation, is involved in Duchenne muscular dystrophy (DMD)
physiopathology. Our results show that muscle-specific RANK deletion (mdx-RANKmko) in dystrophin deficient mdx mice
improves significantly specific force [54% gain in force] of EDL muscles with no protective effect against eccentric
contraction-induced muscle dysfunction. In contrast, full-length OPG-Fc injections restore the force of dystrophic
EDL muscles [162% gain in force], protect against eccentric contraction-induced muscle dysfunction ex vivo and
significantly improve functional performance on downhill treadmill and post-exercise physical activity. Since OPG
serves a soluble receptor for RANKL and as a decoy receptor for TRAIL, mdx mice were injected with anti-RANKL
and anti-TRAIL antibodies to decipher the dual function of OPG. Injections of anti-RANKL and/or anti-TRAIL increase
significantly the force of dystrophic EDL muscle [45% and 17% gains in force, respectively]. In agreement, truncated
OPG-Fc that contains only RANKL domains produces similar gains, in terms of force production, than anti-RANKL
treatments. To corroborate that full-length OPG-Fc also acts independently of RANK/RANKL pathway, dystrophin/RANK
double-deficient mice were treated with full-length OPG-Fc for 10 days. Dystrophic EDL muscles exhibited a significant
gain in force relative to untreated dystrophin/RANK double-deficient mice, indicating that the effect of full-length
OPG-Fc is in part independent of the RANKL/RANK interaction. The sarco/endoplasmic reticulum Ca2+ ATPase (SERCA)
activity is significantly depressed in dysfunctional and dystrophic muscles and full-length OPG-Fc treatment increased
SERCA activity and SERCA-2a expression. These findings demonstrate the superiority of full-length OPG-Fc treatment
relative to truncated OPG-Fc, anti-RANKL, anti-TRAIL or muscle RANK deletion in improving dystrophic muscle function,
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integrity and protection against eccentric contractions. In conclusion, full-length OPG-Fc represents an efficient
alternative in the development of new treatments for muscular dystrophy in which a single therapeutic approach
may be foreseeable to maintain both bone and skeletal muscle functions.
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Introduction
Bone and muscle have the ability to adjust their struc-
tures to meet their mechanical, hormonal, and metabolic
environments. Osteoporosis and muscle atrophy/dys-
function occur simultaneously in a number of condi-
tions, including spaceflight, extended bed rest, and
several muscular and neuromuscular diseases. Local and
systemic alterations in hormone and pro-inflammatory
cytokine levels stimulate muscle and bone atrophy [25,
32]. Changes in intracellular Ca2+ concentrations
regulate the physiological activities and expression of
specific bone and muscle genes [15, 30]. Poor bone
health and increased incidence of bone factures are well
recognized clinically in Duchenne muscular dystrophy
(DMD) patients suggesting cross-talks and mutual co-
operative interactions between bones and dystrophic
muscles [11]. However, the potential cellular and
molecular mechanisms that may tie together bones and
skeletal muscles during physiological and pathological
conditions remain elusive.
The receptor-activator of nuclear factor κB ligand
(RANKL), the membrane receptor RANK, and the sol-
uble decoy receptor osteoprotegerin (OPG) are members
of the tumor necrosis factor (TNF) superfamily that reg-
ulates bone remodelling [19, 27]. RANKL is expressed
by osteoblasts, while RANK, its receptor, is expressed by
pre-osteoclastic cells. The RANK/RANKL interaction in-
duces the formation of multinucleated mature osteo-
clasts, ultimately causing bone resorption [21]. OPG, the
third protagonist, is also produced by osteoblasts, binds
to RANKL and exerts an inhibitory effect on the pre-
osteoclastic differentiation process [2]. Structurally, the
native OPG protein is highly conserved and contains
four TNFR-like domains (RANKL binding sites), two
death domains (tumour necrosis factor-related
apoptosis-inducing ligand [TRAIL binding sites]), and a
heparin-binding domain [31]. Thus, OPG serves as a
decoy receptor for the RANKL and TRAIL and is a very
efficient anti-resorptive and anti-apoptotic agent [3].
The focus of research in our laboratory is to decipher
the potential cellular and molecular mechanisms that
may tie together bones and skeletal muscles during
physiological and pathological conditions. We first hy-
pothesized that RANK/RANKL/OPG pathway, a key
regulator of bone homeostasis and Ca2+ storage, would
contribute in the regulation of skeletal muscle integrity
and function during the course of muscular dystrophy.
We previously demonstrated that daily full-length OPG-
Fc treatment markedly improved muscle function and
integrity in 5 week-old mdx mice [12]. The main object-
ive of this study was to determine the specific contribu-
tion of muscle RANK, RANKL and TRAIL in muscular
dystrophy. Using genetic and pharmacological ap-
proaches in young and adult dystrophic mice, we are
able to show the unequivocal superior effects of full-
length OPG-Fc in rescuing dystrophic muscles relative
to selective muscle RANK deletion or anti-RANKL or
anti-TRAIL treatments. Altogether, our results suggest
that full-length OPG-Fc is a multifunctional protein that
has the potential to impact on several different cellular




Mice carrying the RANKfloxed or RANKdel alleles and
muscle creatine kinase-cre (mck-cre) mice were back-
crossed five times to a C57BL/6 background before gen-
erating the mck-cre RANKdel/floxed (RANKmko) mice as
previously described [13, 20]. Male wild-type (C57BL/6)
and mdx dystrophic mice (C57BL/10ScSn-Dmdmdx/J)
were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA) and bred at our animal facility.
RANKmko mice were also crossed with mdx-background
mice to generate double deficient mice (dystrophin and
RANK). Mice were screened for the desired genotype by
PCR analysis. PCR products were amplified using primer
pairs as listed in Additional file 1: Table S2. Dystrophic
mdx mice were injected daily with full-length OPG-Fc
[12] [i.p., 1 mg/kg/d R&D systems, MN, USA], PBS,
anti-RANKL [39] [1 mg/kg/ every 3 d, clone IK22–5],
anti-TRAIL [22] [1 mg/kg/every 3 d, clone H2B2] or
truncated OPG-Fc [1 mg/kg/d, Syd Labs, MA, USA]
from days 25 to 35 after birth. In another set of experi-
ments, five six-month old mdx mice were injected daily,
for 10 d, with full-length OPG-Fc [i.p. 1 mg/kg/d]
followed by a downhill (eccentric) treadmill running
protocol. C57BL/6 mice were used as a control and
injected daily with the same volume of phosphate-
buffered saline (vehicle). At the end of the experimental
procedures, mice were euthanized by cervical dislocation
under anesthesia and skeletal muscles [extensor
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digitorum longus (EDL), soleus (Sol) and diaphragm
(Dia)] were removed and stored at − 80 °C for future
analysis. All procedures were approved by the Université
Laval Research Center Animal Care and Use Committee,
based on the Canadian Council on Animal Care guide-
lines. All data generated or analysed during this study are
included in this published article and its Additional file 1.
Immunofluorescence and staining
Transverse EDL muscle sections (10 μm) were cut (Leica
Microsystems CM1850, Nussloch, Germany) in dupli-
cate from the proximal and distal parts of the muscles.
Tissue sections stained with hematoxylin and eosin
(Sigma-Aldrich, St. Louis, MO, USA) were examined
with an inverted microscope (Nikon, Ontario, Canada)
and damage, regenerating and intact areas on approxi-
mately 100 myofibers per muscle were quantified with
ImageJ software version 1.41 (National Institutes of
Health, USA). The damaged area was defined as an area
not occupied by normal or regenerating muscle fibers.
Image series of EDL were taken using a confocal micro-
scope (Axio Observer.Z1; Carl Zeiss, Germany) and ac-
quired using a Quorum WaveFX spinning disc confocal
system (Quorum Technologies, Ontario, Canada). Solid
state laser lines 491 nm and 561 nm were used for exci-
tation of green and red (Alexa-488 and Alexa-594), com-
bined with appropriate BrightLine single-bandpass
emission filters (536/40 nm and 624/40 nm, Semrock,
NY, USA). z-series were acquired at the same time with
DAPI fluorescence filter cube (Chroma Technology, VT,
USA). The CCD camera used to capture the images was
a Hamamatsu Image EM C-9100. Images were acquired
and analyzed using Volocity software, version 4.2.1. It-
erative restoration (deconvolution) was applied for the
DAPI channel, using the same software.
Western blots and qPCR
Skeletal muscles were homogenized in a lysis buffer con-
taining 1 μg/ml, protease inhibitor cocktail (P8340; Sigma-
Aldrich, Ontario, Canada), 20 mM Tris-base pH 7.5,
140 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol,
1% Igepal (Sigma-Aldrich, Ontario, Canada), 2 mM
Na3VO4, 8.3 mM NaF and 0.2 mM PMSF. The protein
content of the supernatant was measured using BCA pro-
tein assay kit (EMD chemical, Nussloch Germany). Protein
homogenates were electrophoretically separated on SDS-
polyacrylamide gels, transferred to polyvinylidene difluoride
membranes (PVDF; Bio-Rad, CA, USA), blocked in 5%
skim milk and incubated overnight at 4°C with the follow-
ing primary antibodies (all from Santa Cruz Biotechnology):
anti-SERCA-1a, anti-SERCA-2a anti-RANK and anti-
GAPDH. The membranes were washed and incubated with
appropriate HRP-conjugated secondary antibodies (Santa
Cruz Biotechnology, CA, USA). Bands were revealed using
the ECL-Plus chemiluminescent detection system (Perkin-
Elmer, MA, USA). Images of the membranes were ac-
quired, scanned, and analyzed using Quantity One software
(v4.6.6, Bio-Rad). For RT-PCR analysis (Additional file 1:
Table S2), skeletal muscles were rapidly put in RNAlater
RNA Stabilization Reagent (Qiagen, MD, USA). Total RNA
was isolated using the RNeasy Fibrous Tissue Mini Kit
(Qiagen, MD, USA) according to manufacturer’s instruc-
tions. During isolation process, RNA samples were treated
with RNase-Free DNase Set (Qiagen, MD, USA). RNA
quality was assessed using an Agilent 2100 Bioanalyzer
(Agilent Technologies, CA, USA) and quantified using a
NanoDrop 1000 Spectrophotometer (NanoDrop Technolo-
gies, DE, USA). The expression of the RANK gene in each
sample was compared to the housekeeping gene GAPDH.
Measurements were performed in duplicate for each stand-
ard and muscle sample.
Contractile properties
Mice were injected with buprenorphine (i.p. 0.1 mg/kg)
and were anaesthetized with pentobarbital sodium (i.p.
50 mg/kg) 15 min later. The right Sol and EDL muscles
were resected and attached to a 305B-LR dual-mode lever
arm system controlled by dynamic muscle control unit
and data acquisition software (Aurora Scientific, Aurora,
ON, Canada) as described by Dufresne et al. (2016) [13].
For the eccentric contraction protocol, the muscles were
set at optimal L0 and stimulated at 150 Hz for 700 ms.
Five hundred ms into the stimulation protocol, the mus-
cles were lengthened to 10% of L0 at 0.5 L0/s for 200 ms.
Downhill running protocol
Six month-old C57BL/6 and mdx mice were treated for
10 days with PBS (n = 12) or full-length OPG-Fc [1 mg/
kg/d] (n = 12). From days 7 to 9, mice were trained for
acclimatization on an horizontal (0% grade) motorized
treadmill at 6, 8 and then 10 m/min for 5 min. Following
the training protocol, mice ran on a downhill sloped
(14-degree decline) at 10 m/min for 45 min. Mice were
continually observed during the running protocol.
Exhausted mice showing physical signs of discomfort
were rested for 2 min. The running protocol was discon-
tinued after 3 stops. Following the eccentric protocol,
post-exercise mouse activity was measured by video
tracking software in an open field for 24 h.
SERCA activity
Frozen EDL, Sol and Dia muscles were homogenized
with a ground-glass pestle in 5 volumes of 10 mM Tris/
HCl (pH 8.3) supplemented with 0.3 M sucrose. SERCA
activity was measured in A. R. Tupling’s laboratory with
an assay adapted for a spectrophotometric plate reader
according to Duhamel and colleagues (2007) [14]
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following the oxidation of NADH at 340 nm in assay
buffer (pH 7.0) containing 1 mM EGTA, 10 mM phos-
phoenolpyruvate, 18 U/mL pyruvate kinase and lactate
dehydrogenase, 0.2 mM NADH, 20 mM HEPES,
200 mM KCl, 15 mM MgCl2, 10 mM NaN3, and 5 mM
ATP. The homogenized muscles and assay buffer were
added to tubes containing 15 different concentrations of
Ca2+ (between 7.6 and 4.7 pCa units) in the presence
and absence of ionophore A23187 (4.2 μM). The
absence of the ionophore causes back-inhibition of
SERCA pumps. Then 0.3 mM NADH was added to start
the reaction and the plate was read at a wavelength of
340 nm for 30 min at 37 °C. The different concentra-
tions of Ca2+ were used to determine the maximal
enzyme activity (Vmax) and pCa50. Lastly, cyclopiazonic
acid (CPA; 40 μM), a highly specific SERCA inhibitor,
was used to determine background activity.
Statistical analyses
All values are expressed as means +/− SEM. The data
were analyzed with Student’s t-test or one-way ANOVA
with Tukey post hoc test (InStat). The levels of signifi-
cance was set at *p < 0.05, **p < 0.01, and ***p < 0.001 for
PBS-treated mdx.
Results and discussion
OPG-fc is superior to muscle-specific RANK deletion in
mitigating muscular dystrophy
We previously showed that RANK is expressed in fully
differentiated mouse myotubes, but not in proliferating
Fig. 1 RANK expression in dystrophic skeletal muscles. a A quantitative real-time PCR analysis revealed that muscle RANK expression is increased
by 5.5-fold in dystrophic EDL muscles relative to control. b Confocal images demonstrating the colocalization of dystrophin (green) and RANK
(red) at the basal lamina in EDL muscles from C57BL/6 mice. As expected, dystrophin is not expressed in EDL muscles from mdx mice while dystrophin and
RANK proteins are absent in EDL muscles from mdx-RANKmko mice. H&E staining revealed that EDL muscles from mdx-RANKmko mice had a lesser number
of irregular fiber sizes and accumulation of perimysial connective tissue compared with mdx-RANKf/f muscles. Data are shown as mean +/−
s.e.m. * Significantly different from control C57 EDL muscles, p < 0.05, n = 3, Student’s t-test. Scale bar = 100 μm
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C2C12 myoblasts [13]. Interestingly, RANK mRNA was
5.5 fold higher in EDL muscles from dystrophic mdx
mice relative to C57BL/6 mice (Fig. 1a). To explore
RANK’s contribution in dystrophic skeletal muscle and
compare it with OPG-Fc-mediated RANKL inhibition,
we crossed dystrophic mdx mice with muscle-specific
RANK deletion, thereafter named mdx-RANKmko. Mdx-
RANKfloxed/floxed mice that do not carry the Cre
recombinase, thereafter named mdx-RANKf/f which
appeared indistinguishable from mdx mice served as
littermate controls. Immunohistochemistry results
confirmed the presence of dystrophin in EDL muscles
from C57BL/6 mice and RANK protein on the
membrane of skeletal muscle fibers from C57BL/6 and
mdx mice. Dystrophin and RANK proteins were not
detected in skeletal muscles from mdx-RANKmko mice
(Fig. 1b). We tested whether muscle-specific RANK de-
letion improves structural integrity and muscle function.
Hematoxylin/eosin staining showed that muscle RANK
deletion partially preserved muscle integrity in dys-
trophin/RANK double-deficient mice (Fig. 1b and
Additional file 1: Figure S1). The specific and absolute
force production of Sol, EDL and Dia muscles from mdx
and mdx-RANKf/f mice were similar and significantly
lower than C57BL/6 mice (Fig. 2a and Additional file 1:
Figure S2). Muscle-specific RANK deletion significantly
increased the specific and absolute forces of dystrophic
EDL muscles by 87% and 54%, respectively, when
Fig. 2 Genetic deletion of muscle RANK or selective inhibitions of RANKL or TRAIL in dystrophic mice. a Maximum specific force analysis of the
Sol, EDL and Dia muscles were performed on 5-week-old C57BL/6, mdx-RANKmko, mdx-RANKf/f or mdx mice treated from days 25 to 35 with
vehicle (PBS) or full-length OPG-Fc [1 mg/kg/d]. Uninjured muscles from C57BL/6 mice were used as controls. Full-length OPG-Fc [1 mg/kg/d]
treatments and to a lesser extent, muscle-specific RANK deletion significantly preserved muscle force. b Schematic representations of full-length
OPG-Fc, truncated OPG-Fc, RANKL and TRAIL antibodies. c Contractile properties of EDL muscles were performed on 5-week-old mdx mice treated
from days 25 to 35 with anti-RANKL or/and anti-TRAIL antibodies or truncated OPG-Fc. The inhibition of RANKL and TRAIL for 10 days increased
the force production of dystrophic EDL muscles by 45% and 17% respectively. The truncated OPG-Fc had similar effects than anti-RANKL, increasing
the force production of EDL muscles by 43%, which were markedly lower than that of dystrophic EDL muscles from full-length OPG-Fc treated mdx
mice (+ 162%). d To explore whether full-length OPG-Fc acts independently of RANKL/RANK, mdx-RANKmko mice were treated from days 25 to 35 with
full-length OPG-Fc [1 mg/kg/d], and showed additional gain in force relative to PBS-treated mdx-RANKmko mice. The dotted line is the visual representation
of full-length OPG-Fc data. Data are shown as mean +/− s.e.m., one way ANOVA and Tukey’s post-hoc tests; significantly different from PBS-treated mdx
mouse; * p< 0.05, ** p< 0.01, *** p< 0.001
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compared to the PBS-treated mdx mice (Fig. 2a and
Additional file 1: Figure S2). Although to a lower extent
than dystrophic EDL muscles, specific and absolute
forces of Sol and Dia muscles were also improved in
mdx-RANKmko relative to mdx-RANKf/f mice (Fig. 2a
and Additional file 1: Figure S2). Similar gains in force
were observed in 15 month-old mdx-RANKmko relative
to mdx-RANKf/f mice (Additional file 1: Figure S3).
Hematoxylin/eosin staining confirmed that muscle
integrity was strongly preserved in the full-length OPG-
treated mdx mice (Additional file 1: Figure S4). Surpris-
ingly, OPG-Fc almost completely restored EDL muscle
force to wild type levels and was significantly more ef-
fective than muscle RANK deletion during the most se-
vere phase of muscle degeneration in mdx mice (Fig. 2a
and Additional file 1: Figure S2). Given the high respon-
siveness of the EDL muscle to OPG-Fc treatment and
that fast-twitch muscles are vulnerable to DMD, we
chose to use this muscle for the remaining of the study.
Since full-length OPG-Fc was significantly more effect-
ive compared to muscle-specific RANK deletion in pre-
serving muscle function during the most severe phase of
degeneration in mdx mice, we next focused to determine
the contribution of the different OPG domains to the
preservation of muscle integrity (Fig. 2b). OPG is a sol-
uble receptor for RANKL and a decoy receptor for
TRAIL increasing cell survival by blocking the pro-
apoptotic effects of the TRAIL/DR4–5 interaction [16,
33]. To determine the dual function of OPG and the im-
plication of the RANKL and TRAIL domains, mdx mice
were injected with anti-RANKL and anti-TRAIL anti-
bodies (Fig. 2b). The inhibition of RANKL and TRAIL
for 10 days increased the specific force production of
dystrophic EDL muscles by 45% and 17%, respectively,
which are markedly lower than full-length OPG-Fc
treated mdx mice (162%) (Fig. 2c). Furthermore, the
combination of anti-RANKL and anti-TRAIL was not
superior to anti-RANKL treatment alone (Fig. 2c). To
confirm the exclusive efficiency of full-length OPG-Fc,
mdx mice were also treated with the truncated form of
OPG-Fc that carries RANKL-binding domains (Fig. 2c).
As expected, the truncated OPG-Fc had similar effects
to anti-RANKL treatment, increasing by 48% the force
production of dystrophic EDL muscles (Fig. 2c). To cor-
roborate whether full-length OPG-Fc also acts independ-
ently of RANK/RANKL pathway, dystrophin/RANK
double-deficient mice were treated with full-length
OPG-Fc for 10 days. Dystrophic EDL muscles exhibited
Fig. 3 Full-length OPG-Fc, but not muscle RANK deletion, prevents eccentric contraction-induced muscle dysfunction. a Ex vivo eccentric contraction
protocol of EDL muscles were performed on 5-week-old C57BL/6, mdx-RANKmko and mdx mice treated from days 25 to 35 with vehicle (PBS) or
full-length OPG-Fc [1 mg/kg/d]. Full-length OPG-Fc, but not muscle RANK deletion, significantly prevented the loss of force following repetitive
eccentric contractions. Functional performance was assessed on 5–6-month-old mdx mice treated with vehicle (PBS) or full-length OPG-Fc
[1 mg/kg/d] for 10 days prior downhill running. b Only 10% of the PBS-treated versus 75% of the full-length OPG-Fc treated mdx mice were
able to complete the downhill running protocol at a speed of 10 m/s for 45 min. c The total distance travelled at 10 m/min for 45 min (450 m) for each
experimental group. d The full-length OPG-Fc treatment rescued the voluntary cage activity post- exhausting eccentric downhill running. Data are
shown as mean values +/− s.e.m.; one way ANOVA and Tukey’s post-hoc; significantly different at (a) each contraction or (b-d) each time point from
PBS-treated mdx mouse; * p < 0.05, ** p < 0.01, *** p < 0.001
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a significant gain in force (29%) relative to untreated
dystrophin/RANK double-deficient mice, indicating that
full-length OPG-Fc can act in part independently of the
RANKL/RANK interaction (Fig. 2d). All treatments and
muscle RANK deletion did not change muscle mass
(Additional file 1: Table S1). Our results show that anti-
RANKL, anti-TRAIL, truncated OPG-Fc treatments or
RANK deletion are much less effective than full-length
OPG-Fc against muscular dystrophy (Additional file 1:
Figure S5).
Full length OPG-fc, but not muscle RANK deletion, prevents
eccentric contraction-induced muscle dysfunction.
Dystrophic muscles are vulnerable to repetitive eccen-
tric contractions [6, 17] and as opposed to muscle
RANK deletion, full-length OPG-Fc positively improved
EDL muscle resistance to repeated eccentric contrac-
tions (Fig. 3a), conferring a role for full-length OPG-Fc
that is beyond the inhibition of RANKL/RANK interac-
tions. To test whether the full-length OPG-Fc treat-
ment provides a similar protection in vivo during a
physiological eccentric protocol, PBS- and OPG-Fc
treated adult mdx mice were subjected to a 45-min
downhill eccentric running protocol. Ten percent of
PBS-treated versus 75% of the full-length OPG-Fc
treated dystrophic mice were able to complete the en-
tire downhill running protocol (Fig. 3b). The first stop
for the PBS-treated mdx mice occurred on average after
17 min of downhill running, while full-length OPG-Fc
treated mdx mice stopped for the first time after
32 min (Additional file 1: Figure S6a). The PBS and
full-length OPG-Fc treated mice that failed to complete
the eccentric protocol did, respectively, 63% and 91% of
the expected distance (Additional file 1: Figure S6b).
The total distance travelled for the PBS-treated mdx
mice was 282 m, while full-length OPG-Fc treated mdx
Fig. 4 Full-length OPG-Fc treatment increased SERCA activity and SERCA-2a protein levels in fast-twitch dystrophic EDL muscles. a Full-length
OPG-Fc [1 mg/kg/d] treatment, but not muscle RANK deletion, increased SERCA activity over different Ca2+ concentrations ranging from pCa
7,0–4,5 in homogenized dystrophic EDL muscles (b) with no change in pCa50 value. c Full-length OPG-Fc treatment rescued maximal ATPase
activity (Vmax) in dystrophic EDL muscles. d Consistent with an increase in SERCA activity, full-length OPG-Fc markedly enhanced 6-fold SERCA-2a
protein levels but not SERCA-1a, compared to PBS-treated mdx mice. Data are shown as mean values +/− s.e.m.; one way ANOVA and Tukey’s
post-hoc tests; significantly different from PBS-treated mdx mouse; * p < 0.05, ** p < 0.01
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mice completed 409 m (Fig. 3c). Following the strenu-
ous eccentric protocol, mouse voluntary activity was
measured by video-tracking software for 24 h. The
full-length OPG-Fc treatment enhanced cage activity
by roughly 50% at any given time point during the
24 h period (Fig. 3d and Additional file 1: Figure S7).
Thus, our functional ex vivo and in vivo experiments
provide physiological evidence that full-length OPG-
Fc is very effective in protecting young and adult dys-
trophic mice against eccentric contraction-induced
muscle dysfunction.
Full-length OPG-fc, but not muscle-specific RANK deletion,
increases SERCA activity and expression in dystrophic EDL
muscles
We previously showed that muscle RANK is important
in maintaining SERCA activity [13]. Since SERCA over-
expression in skeletal muscles reduces susceptibility to
eccentric contraction-induced muscle damage in dys-
trophin and sarcoglycan-null mice and given that intrin-
sic laryngeal muscles that overexpress SERCA are
protected against muscular dystrophy [18, 29], we tested
whether full-length OPG-Fc injections for 10 days might
also enhance SERCA activity and SERCA-1a and
SERCA-2a protein levels in fast-twitch dystrophic EDL
muscles. Maximal SERCA activity is significantly de-
pressed in dystrophic EDL muscles and full-length
OPG-Fc treatment restored almost completely its activ-
ity (Fig. 4a-c). The protein levels of fast-twitch SERCA-
1a were diminished in dystrophic EDL muscles and full-
length OPG-Fc treatment selectively increased by 6-fold
the expression of the slow-twitch SERCA-2a. (Fig. 4d).
However, muscle-specific RANK deletion did not in-
crease maximal SERCA activity in dystrophic EDL, Sol
and Dia muscles (Fig. 4a-c and Additional file 1: Figure
S8a-f ), providing additional evidence that full-length
OPG-Fc could act through alternative pathways and
may potentially rescue Ca2+ cycling/homeostasis
through SERCA-2a dependent mechanism.
Perspective and conclusion
In the early 2000s, truncated OPG-Fc (AMGN-0007)
reached clinical trial for the treatment of osteoporosis
and bone metastasis [5, 7]. Truncated and full-length
OPG-Fc can interact with RANKL preventing the down-
stream activation of NF-kB, a key controller of many
genes involved in inflammation. Our observations that
muscle-specific RANK deletion, anti-RANKL or trun-
cated OPG-Fc and full-length OPG-Fc treatment protect
fast-twitch fibers are of paramount importance, since
these powerful fibers are the first to disappear in many
forms of myopathies [28, 38]. However, we uncover a
unique and superior role for full-length OPG-Fc in pro-
tecting muscle function and integrity in the mdx model
of muscular dystrophy. Since full-length OPG-Fc rescues
SERCA activity in fast-twitch dystrophic skeletal mus-
cles, we anticipate that full-length OPG-Fc treatment
would contribute to normalize SR Ca2+ regulation in
muscular dystrophy by removing Ca2+ from the
myoplasm and refilling the internal Ca2+ stores through
the action of SERCA pumps. The stimulation of SERCA
pumps should lead to better Ca2+ mobilization breaking
the vicious cycle of muscle inflammation and Ca2
+-dependent protease activation initiated by poor Ca2+
handling [9, 35].
Current investigations are oriented toward the various
roles of full-length OPG-Fc. Bone, tumor cells, inflam-
matory cells and vascular cells have given some insight
on how full-length OPG-Fc may work to some extent in-
dependently of RANKL inhibition in muscular dystrophy
[4]. Native OPG possesses a heparin-binding domain
that may interact with various glycoaminoglycans and
proteoglycans and ultimately integrins [23, 24, 26, 34,
36, 40]. In addition, heparan-sulfate proteoglycans are
abundant in skeletal muscles [8], increases in DMD [1]
and may represent an additional target for full-length
OPG-Fc [10]. On the other hand, it was recently found
that integrin-linked kinase, the adaptor protein of integ-
rins mediates force transduction in cardiomyocytes
through SERCA-2a function [37]. It is thus tempting to
speculate that full-length OPG-Fc-induced SERCA2a
Fig. 5 Schematic representation of the signaling pathways through
which full-length OPG-Fc may exert its effects on skeletal muscle.
The full-length OPG-Fc binds to RANKL and TRAIL limiting inflammation
and apoptotic pathways and also binds to an unknown muscle receptor
stimulating SERCA activity and Ca2+ entry thereby favouring Ca2+ cycling
and homeostasis and ultimately muscle performance
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expression may also act through mutual cooperation
between proteoglycans, integrins and growth factors
(Fig. 5). Altogether, our results suggest that all 7 do-
mains of OPG-Fc may contribute to prevent muscle
degeneration in DMD. Since OPG is a well-known bone
protector, one cannot exclude that healthier bones may
also protect dystrophic muscles but this remains well be-
yond the scope of the present study. In conclusion, full-
length OPG-Fc may be a new clinical treatment for several
forms of neuromuscular and muscular diseases in which a
single therapeutic approach may be foreseeable to main-
tain both bone and skeletal muscle functions.
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